Literature DB >> 12824197

Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.

Sarah Pressman Lovinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12824197     DOI： 10.1001/jama.289.24.3229

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Infliximab and serious hematologic events.

Authors:  Cynthia Phelan; Eric Wooltorton
Journal:  CMAJ       Date:  2004-10-26       Impact factor: 8.262

Review 2.  An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.

Authors:  Nick J Bansback; Dean A Regier; Roberta Ara; Alan Brennan; Kamran Shojania; John M Esdaile; Aslam H Anis; Carlo A Marra
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Biological drug use: US perspectives on indications and monitoring.

Authors:  J J Cush
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 4.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Multidimensional Model of Disability and Role Functioning in Rheumatoid Arthritis.

Authors:  Sarah R Ormseth; Taylor L Draper; Michael R Irwin; Michael H Weisman; Adam E Aréchiga; Narineh Hartoonian; Thuy Bui; Perry M Nicassio
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-12       Impact factor: 4.794

6.  Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank.

Authors:  Esi Morgan DeWitt; Li Lin; Henry A Glick; Kevin J Anstrom; Kevin A Schulman; Shelby D Reed
Journal:  Clin Ther       Date:  2009-08       Impact factor: 3.393

7.  The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines.

Authors:  Christine Y Lu; Kenneth M Williams; Richard O Day
Journal:  Aust New Zealand Health Policy       Date:  2007-03-01

8.  Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice.

Authors:  Hsin-Hua Chen; Der-Yuan Chen; Ya-Hsuan Chao; Yi-Ming Chen; Chao-Liang Wu; Kuo-Lung Lai; Ching-Heng Lin; Chi-Chen Lin
Journal:  Sci Rep       Date:  2015-12-18       Impact factor: 4.379

9.  Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity.

Authors:  Kichul Shin; Sung Soo Kim; Sang-Heon Lee; Seung-Jae Hong; Sung Jae Choi; Jung-Yoon Choe; Seung-Geun Lee; Hoon-Suk Cha; Eun Young Lee; Sung-Hwan Park; Jin-Wuk Hur; Sung Soo Na; Chang-Hee Suh; Min Wook So; Seung Won Choi; Dong-Hyuk Sheen; Won Park; Shin-Seok Lee; Wan Hee Ryu; Jin Seok Kim; Jung Soo Song; Hye Soon Lee; Seong Ho Kim; Dae-Hyun Yoo
Journal:  Korean J Intern Med       Date:  2019-01-28       Impact factor: 2.884
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.